'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_159006

Gene identified that plays a key role in severity of colon cancer

13 September 2021
Appeared in BioNews 1112

A lack of a specific gene in immune cells of patients with colon cancer has been linked with a much more dangerous form of the disease.

Regulatory T cells (Treg cells) are specialised white blood cells that function to down-regulate immune responses, playing an important role in preventing autoimmunity. However, in cancer they can suppress the immune system's attempts to get rid of a growing tumour, allowing cancer to progress and the disease to become more severe. In patients with colon cancer, the transcription factor TCF1 was found to be missing in the Treg cells within the tumour.

'It's extremely important to be able to manage the degree of immune response,' Dr Majid Kazemian, from Purdue University, Indiana, who led the study said. 'That's why understanding these Treg cells is so important. If you have too much of a response, you get autoimmunity. If you have too little, you get cancer. Healthy systems need to strike a balance between autoimmune disease and cancer, and proper Treg cell function plays a key role in doing that.'

Transcription factors are proteins that control the rate that genetic information is copied. Published in Nature Immunology the scientists found that in the absence of TCF1 the Treg cells became inflammatory, multiplying and moving to the intestine and gut, leading to more serious tumours that are much harder to treat.

The research was limited as the interaction between TCF1 and Treg cells was only observed in mice. The activity of Treg cells where TCF1 had been artificially removed in mice was compared to the activity of Treg cells in human patients with colon cancer. Further research confirming a similar pathway in humans is required.

Future drug developers may be able to use the TCF1 gene pathway to manipulate regulatory T cells in the treatment of colon cancers. In addition, presence of cells in the colon which lack TCF1 could help oncologists to better understand a patient's prognosis.

In the UK, colon cancer is the fourth most common type of cancer and accounts for ten percent of all cancer deaths.

SOURCES & REFERENCES
A gene that controls the severity of colon cancer
Purdue University |  7 September 2021
TCF-1 controls Treg cell functions that regulate inflammation, CD8+ T cell cytotoxicity and severity of colon cancer
Nature Immunology |  12 August 2021
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
8 February 2021 - by Christina Burke 
Disrupting a specific protein interaction causes tumours to shrink, researchers in the US have found...
17 December 2018 - by Martha Henriques 
Two genetic markers linked to an aggressive, treatment-resistant form of colorectal cancer...
12 December 2016 - by Ayala Ochert and Ebtehal Moussa 
Researchers have successfully treated a woman with colon cancer using her own immune cells to target a cancer-causing gene that had previously been considered 'undruggable'...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.